SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "L773:1871 6784 OR L773:1876 4347 ;mspu:(researchreview)"

Search: L773:1871 6784 OR L773:1876 4347 > Research review

  • Result 1-3 of 3
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Landegren, Ulf, et al. (author)
  • A myopic perspective on the future of protein diagnostics
  • 2018
  • In: New Biotechnology. - : ELSEVIER SCIENCE BV. - 1871-6784 .- 1876-4347. ; 45, s. 14-18
  • Research review (peer-reviewed)abstract
    • Plasma proteome analyses of the future promise invaluable insights into states of health, not only by measuring proteins whose role it is to ensure blood homeostasis, but increasingly also as a window into the health of practically any tissue in the body via so-called leakage protein biomarkers. Realizing more of this vast potential will require progress along many lines. Here we discuss the main ones, such as optimal selection of target proteins, affinity reagents, immunoassay formats, samples, and applications, with a view from ongoing work in our laboratory.
  •  
2.
  • McGinn, Steven, et al. (author)
  • New Technologies for DNA analysis-A review of the READNA Project.
  • 2016
  • In: New Biotechnology. - : Elsevier BV. - 1876-4347 .- 1871-6784.
  • Research review (peer-reviewed)abstract
    • The REvolutionary Approaches and Devices for Nucleic Acid analysis (READNA) project received funding from the European Commission for 4 1/2 years. The objectives of the project revolved around technological developments in nucleic acid analysis. The project partners have discovered, created and developed a huge body of insights into nucleic acid analysis, ranging from improvements and implementation of current technologies to the most promising sequencing technologies that constitute a 3(rd) and 4(th) generation of sequencing methods with nanopores and in situ sequencing, respectively.
  •  
3.
  • Zieba, Agata, et al. (author)
  • Molecular tools for companion diagnostics
  • 2012
  • In: New Biotechnology. - : Elsevier BV. - 1871-6784 .- 1876-4347. ; 29:6, s. 634-640
  • Research review (peer-reviewed)abstract
    • The heterogeneous nature of cancer results in highly variable therapeutic responses even among patients with identical stages and grades of a malignancy. The move towards personalised medicine in cancer therapy has therefore been motivated by a need to customise therapy according to molecular features of individual tumours. Companion diagnostics serves to support early drug development, it can provide surrogate markers in clinical trials, and also guide selection of individual therapies and monitoring of responses in routine clinical care. The era of companion diagnostics can be said to have begun with the introduction of the HercepTest - a first-of-a-kind diagnostic tool developed by DakoCytomation in 1998 to select patients for therapy with the anticancer drug Herceptin (trastuzumab). Herceptin and the paired test proved that companion diagnostics can help guide patient-tailored therapies. We will discuss herein technologies to analyse companion diagnostics markers at the level of DNA, RNA or protein, focusing on a series of methods developed in our laboratory that can facilitate drug development and help stratify patients for therapy.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-3 of 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view